Onyx Pharmaceuticals Inc. is prepared to move fast with the launch of its second-generation multiple myeloma drug Kyprolis (carfilzomib), with dedicated sales reps hitting prescribers within days and orders opening within a week and a half of approval.
The next-generation proteasome inhibitor was cleared via FDA’s accelerated approval pathway July 20 for treatment of multiple myeloma patients who...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?